Antibody Drug Conjugates for Cancer Therapy
Antibody Drug Conjugates for Cancer Therapy Antibody Drug Conjugates for Cancer Therapy
In Vivo Efficacy is Retained With TDC FormatOVCAR-3 xenograft tumors in mammary fat padADC (1.5 mg/kg = 71 µg/m 2 )Tumor volume (mm 3 )vehicleTDC (1.5 mg/kg = 35 µg/m 2 )3 mg/kg (69 or 141 µg/m 2 )6 mg/kg (139 or 283 µg/m 2 )Days after single IV dose32
TDC is Better Tolerated than ADC by RatsDay 5 PMN(1000/µL)Weight change (g)TDC 36 mg/kgDay 5 AST(U/L)ADC 16 mg/kgmg/kg:V16 25 36 68 100ADCTDC
- Page 1 and 2: Antibody Drug Conjugates for Cancer
- Page 3: Target Screening- Large scale mRNA-
- Page 6 and 7: Naked antibodies are likely to be i
- Page 9 and 10: How many xenograft models should we
- Page 11 and 12: RelativeTenB2 expression in human p
- Page 13 and 14: Antibodies armed with auristatinsAN
- Page 15: MRP4 (multi drug resistance protein
- Page 18 and 19: Structure of the MUC16 antigen and
- Page 20 and 21: Endothelin B receptor: A target for
- Page 22 and 23: Melanocytes and EDNBR staining in n
- Page 24 and 25: Increased cell killing in vitro wit
- Page 26 and 27: ETBR Expression in Cell Lines versu
- Page 28 and 29: Efficacy/SafetyFour ways for armed
- Page 30 and 31: Antibody doses are normalized to dr
- Page 34 and 35: Cumulative toxicity from long-lived
- Page 36: • GNE ADC Team- Susan Spencer- Ke
In Vivo Efficacy is Retained With TDC FormatOVCAR-3 xenograft tumors in mammary fat padADC (1.5 mg/kg = 71 µg/m 2 )Tumor volume (mm 3 )vehicleTDC (1.5 mg/kg = 35 µg/m 2 )3 mg/kg (69 or 141 µg/m 2 )6 mg/kg (139 or 283 µg/m 2 )Days after single IV dose32
Change language